TCS launches ADD size feasibility platform for life sciences companies

Tata Consultancy Services has launched the ADD (Advanced Drug Development) size feasibility platform which provides life sciences companies with a single, integrated platform that digitises the site selection and activation processes, and facilitates data-driven decision-making while assessing site feasibility for multi-site clinical trials.

In the planning of a clinical study, selection of the right sites for the clinical trials, with the right patient population, investigator profiles, treatment facilities and other parameters, has a huge impact on the study outcomes. Earlier, this critical activity was done manually which resulted in significant delays and costs. TCS’s new feasibility platform addresses this critical problem which is faced by the life sciences companies.

The new platform consolidates data currently residing on multiple systems within the enterprise into a central knowledge repository from which it derives insights that can be used to identify the sites best suited for a given study protocol, with the most appropriate patient population and investigators. It digitises and automates the entire assessment and selection process, enabling the efficient and coordinated management of hundreds of concurrent clinical trial feasibility studies. It also provides customers with an end-to-end solution for conducting site surveys and analysing the survey responses.

A leading life sciences company is the first customer to go live with the TCS ADD Site Feasibility Platform. The flexible design enabled rapid implementation within 10 months.

On Thursday, the stock of TCS opened at Rs. 2,206 per share. During the day, the stock made an intra-day high and intra-low of Rs. 2,217 and Rs. 2,181.20, respectively during the morning trading session.